検索
Korro Bio Inc
KRROウォッチリストに追加
12.170USD
-1.600-11.62%
終値 06/25, 16:00（ET）15分遅れの株価
175.52M時価総額
損失額直近12ヶ月PER
詳細情報 Korro Bio Inc 企業名
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Korro Bio Incの企業情報
企業コードKRRO
会社名Korro Bio Inc
上場日Oct 03, 2019
最高経営責任者「CEO」Dr. Ram Aiyar, Ph.D.
従業員数104
証券種類Ordinary Share
決算期末Oct 03
本社所在地One Kendall Square. Building 600-700
都市CAMBRIDGE
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号02139
電話番号16174681999
ウェブサイトhttps://www.korrobio.com/
企業コードKRRO
上場日Oct 03, 2019
最高経営責任者「CEO」Dr. Ram Aiyar, Ph.D.
Korro Bio Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
18.10K
-18.69%
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
16.96K
-18.67%
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Dr. Jean-Francois Formela, M.D.
Dr. Jean-Francois Formela, M.D.
Independent Director
Independent Director
--
--
Mr. Timothy R. Pearson
Mr. Timothy R. Pearson
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
Dr. Rachel Meyers, Ph.D.
Dr. Rachel Meyers, Ph.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
18.10K
-18.69%
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
16.96K
-18.67%
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Dr. Jean-Francois Formela, M.D.
Dr. Jean-Francois Formela, M.D.
Independent Director
Independent Director
--
--
よくある質問
Korro Bio Incの上位5名の株主は誰ですか？
Korro Bio Incの上位5名の株主は以下のとおりです。Dr. Nessan Bermingham, Ph.D.
Korro Bio Inc（KRRO）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Korro Bio Incの株式を保有している機関は215社あり、保有株式の総市場価値は約11.84Mで、全体の86.30%を占めています。2025Q4と比較して、機関の持ち株は782639.00増加しています。
